BUFFALO, N.Y., Dec. 20 /PRNewswire/ -- MINRAD INC. (http://www.minrad.com/) today announced that it has begun US distribution of its inhalation anesthetic products for the human market through RxElite, Inc. (http://www.rxelite.com/), Boise, Idaho. RxElite has begun to market the company’s two branded generic drugs: Terrell (isoflurane USP), and Compound 347 (enflurane USP) under the RxElite label. Ross Terrell, Ph.D. a MINRAD Research Fellow, invented isoflurane, enflurane, and desflurane while previously working for Airco, Inc. and BOC Health Care. The exclusive agreement with RxElite includes successor inhalation anesthetic products.
Kirk Kamsler, Senior Vice President of Commercial Development, explained MINRAD’s change in distribution, “Several components entered into our decision to partner our inhalation anesthetic line in the United States with RxElite; we were impressed by the energy of the RxElite team, their existing involvement in inhalation respiratory drugs, their current relationships with GPO’s, and this agreement in the U.S. market is consistent with the Company’s global distribution strategy for inhalation anesthetic products.”
For further information please contact: Kirk Kamsler, SVP Commercial Development, MINRAD Inc., 716-855-1068 (kkamsler@minrad.com) or Daniel Chen, CEO, RxElite, Inc., 208-288-5550 (dan@rxelite.com).
FORWARD-LOOKING STATEMENTS
This information contains certain forward looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including or related to our future results (including certain projections, business trends and assumptions on future financings).
Assumptions related to forward-looking statements involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions and financings, all of which are difficult or impossible to predict. When used in this presentation, the words or statements that relate to future events and our future financial performance, such as “may,” “will,” “should,” “expect,” “scheduled,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “potential,” or “continue” or the negative of such terms or other similar words, are intended to be forward- looking statements. You should read these statements carefully because they discuss our future expectations, and we believe that it is important to communicate these expectations to our stockholders. However, these statements are only anticipations. Actual events or results may differ materially.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, future financings, performance, or achievements. Moreover, we do not assume any responsibility for accuracy and completeness of such statements in the future. We do not plan to update any of the forward-looking statements after the date of this presentation to conform such statements to actual results.
MINRAD Inc.
CONTACT: Kirk Kamsler, SVP Commercial Development of MINRAD Inc.,+1-716-855-1068, or kkamsler@minrad.com; or Daniel Chen, CEO of RxElite, Inc.,+1-208-288-5550, or dan@rxelite.com
Web site: http://www.rxelite.com/
Web site: http://www.minrad.com/